Concepedia

Adrian Tersteegen

AT

13

Publications

1.3K

Citations

13

H-Index

1997

Active since

Affiliations

Bayer (Germany)(Current)

Max Planck Institute for Terrestrial Microbiology

Bayer (United States)

Adrian Tersteegen is an author at Bayer (Germany) specializing in medicine, pharmacology, and biochemistry.

Top concepts

Publications per year

1997–2023

13

Publications

13

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

Johannes‐Peter Stasch, Péter Schmidt, Pavel I. Nedvetsky et al. · Journal of Clinical Investigation · 2006 · 443 citations · Full text

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents

F. Josef van der Staay, Kris Rutten, Lars Bärfacker et al. · Neuropharmacology · 2008 · 175 citations · Full text

, , +6

Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line

Frank Wunder, Adrian Tersteegen, Annegret Rebmann et al. · Molecular Pharmacology · 2005 · 144 citations

<i>Methanobacterium thermoautotrophicum</i> encodes two multisubunit membrane‐bound [NiFe] hydrogenases

Adrian Tersteegen, Reiner Hedderich · European Journal of Biochemistry · 1999 · 109 citations

, , +14

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase

Colin W. Garvie, Xiaoyun Wu, Malvina Papanastasiou et al. · Nature Communications · 2021 · 86 citations · Full text

Rows per page

1–5 of 13